



**SARC Semi-Annual Meeting Agenda
CTOS – November 5, 2015**

8:00	Welcome	
		R Lor Randall/Denise Reinke
8:05	Chawla/Rosenfeld Developmental Therapeutics Symposium	
	Introduction and Overview	David Kirsch/Robert Maki
	Implications of SDH loss in the development of GIST	Paul Meltzer
	The role of PRC2 components in the development of malignant peripheral nerve sheath tumors	Ping Chi
	The BAF complex in synovial and other sarcomas	Cigall Kadoch
	LSD: The epigenetic landscape of Ewing sarcoma	Steve Lessnick
	<i>Discussion/Q&A</i>	Symposium Faculty
9:45	Genomic Portal	
		Chand Khanna
9:55	SARC Bio Specimen Bank	
		David Kirsch
10:00	Break	
10:15	SARC Career Development	
	Career Development 2016 Program	Richard Gorlick & Lee Helman
	Evaluation of the contributions of candidate GIST-relevant pathways in GIST malignancy	Cesar Serrano Garcia
	Dystrophin inactivation in GIST: Potential mediator of invasion and metastasis, and clinical applications	Armelle Dufresne
	Predicting doxorubicin sensitivity in soft tissue sarcoma	James Chen
	<i>Discussion/Q&A</i>	Panel
11:00	SARC Clinical Trials	
	Introduction: SARC overall study principal investigator	Scott Okuno
	SARC016: Phase 2 trial of bevacizumab & everolimus in unresectable or metastatic MPNST	Brigitte Widemann
	SARC018/SPORE 2: Phase 2 trial of mocetinostat and gemcitabine in metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy	Edwin Choy/Shreyas Patel
	SARC021: Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic STS	William Tap
	SARC023: Phase 2 trial of ganetespib & sirolimus in unresectable or metastatic MPNST	Aerang Kim/ Brigitte Widemann
	SARC024: Phase 2 trial of regorafenib in refractory lipo, osteo and Ewing/Ewing-like sarcomas	Lara Davis/Richard Riedel/ Chris Ryan/Steve Attia/ Robert Maki
	SARC025/ESP1/SPORE 3: Phase 1 trial of niraparib and temozolomide in incurable Ewing sarcoma	Sandra Strauss/Rashmi Chugh
	SARC028: Phase 2 trial of the anti-PD1 Antibody pembrolizumab in advanced sarcoma	Melissa Burgess/ Hussein Tawbi
	SARC029: Phase 2 trial of trametinib & pazopanib in metastatic or local-regionally recurrent GIST refractory or intolerant to imatinib and sunitinib	Kristen Ganjoo/ Suzanne George
11:45	Adjourn	

THANK YOU

SARC would like to acknowledge the generous support of the following companies.

Platinum Level



Gold Level



If you are interested in learning how to support SARC and more about the funding levels, please feel free to contact SARC directly.

Email: sarc@sarctrials.org or 734-930-7600.



SARC